Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 13 Leukemia, Biphenotypic, Acute 7 Burkitt Lymphoma 6 Prostatic Neoplasms 5 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4 Neoplasms 2 Leukemia, Myeloid, Acute 2 Down Syndrome 2 Stomach Neoplasms 1 Sarcoma 1 Rhabdoid Tumor 1 Recurrence 1 Pyloric Stenosis, Hypertrophic 1 Prostate Cancer Metastatic 1 Pinealoma 1 Pancreatitis 1 Pancreatic Neoplasms 1 Pancreatic Intraductal Neoplasms 1 Ovarian Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Neuroblastoma 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Medulloblastoma 1 Lymphoma, T-Cell 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Leukemia, Myelomonocytic, Juvenile 1 Leukemia 1 Hodgkin Disease 1

Interventions

Radiosurgery 3 Androgen Antagonists 3 Prednisone 2 Docetaxel 2 Abiraterone Acetate 2 fludrocortisone acetate 1 enzalutamide 1 darolutamide 1 apalutamide 1 Standard of Care 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Pluvicto 1 Midazolam 1 Lutetium-177 1 Lutetium 1 Hydrocortisone 1 Gonadotropin-Releasing Hormone 1 Dexamethasone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Prostate Cancer Metastatic × Hydrocortisone × 1 year × Clear all

NCT06136624 2026-05-05

OMAHA-003

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡